Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea with Potent Antiretroviral Therapy in Acute HIV
NCT00006339Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of hydroxyurea in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Plasma HIV-1 RNA Level at 104 weeks and Safety and Tolerability at 104 weeks. Status: withdrawn.
02
Drugs
hydroxyurea
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00006339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006339.